☰ Menu

Blog

Please note most of these publications were published by our predecessor company CellPoint, LLC.

MedAxiom Announces Industry Partnership With Cell>Point

MedAxiom Announces Industry Partnership With Cell>Point with Video Cell>Point, improving lives through imaging and targeted therapy. Partner News…

Read

Cell>Point plans to expedite research program on 99mTc-EC-Amifostine and 177Lu-EC- Amifostine as a potentially effective theranostic technology for COVID-19

CENTENNIAL, Colorado, March 24, 2020 – Cell>Point announced today its plans to move forward with its research program…

Read

Cell>Point Expanding Theranostic Clinical Research to Include Platinum and 177Lu Targeted Therapy to Compliment Oncardia Imaging Platform

CENTENNIAL, Colorado, January 21, 2020 – Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted…

Read

Cell>Point announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the new one-vial Oncardia

CENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its…

Read

CellPoint, L.L.C. announced today that it has entered into automated production agreement with KP Pharmaceutical Technologies for lead molecular imaging agent Oncardia®

CENTENNIAL, Colorado, September 18, 2018 – CellPoint announced today that it has entered into an automated production agreement with…

Read

Noninferiority of 99mTc Ethylenedicystein Glucosamine (Oncarida) as a Alternative Analogue to 18F Flurodeoxyglucose in the Detection and Staging of Non Small Cell Lung Cancer

Published March 19, 2018, Hindawi Contrast Media & Molecular Imaging https://celltheranostics.com/wp-content/uploads/2019/11/Noninferiority-of-99mTc-Ethylenedicystein.pdf

Read

Targeting the Hexosamine Biosynthetic Pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma

Oncotarget, Advance Publications 2016 https://celltheranostics.com/wp-content/uploads/2019/11/12413-186535-1-PB-2016-EC-G-Paper.pdf

Read

Cell>Point enters into license agreement with Vyripharm Biopharmaceuticals for the use of Cell>Point’s In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology

CENTENNIAL, Colo., August 24, 2016  – Cell>Point today announced it has entered into license agreements with Vyripharm Biopharmaceuticals for…

Read

Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia® for Cancer and Heart Disease Diagnostic Imaging

CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for…

Read

Cell>Point Announces Postive Results from 99mTc-Oncardia® (EC- G) trial at the Unviersity of Chicago Medical Center to image and montior therapy for Head and Neck Cancer.

CENTENNIAL, Colo., January 15, 2015 – Cell>Point announced today positive results following conclusion of a Head and Neck…

Read

Patched Targeted Peptides for Imaging and Treatment of Hedgehog Positive Breast Tumors

Published: September 2014, Bio Medical Research International https://celltheranostics.com/wp-content/uploads/2019/11/Patched-Targeting-Peptides-for-Imaging-and-Treatment-of-Hedgehog-Postive-Breast-Tumors.pdf

Read

Cell>Point Announces Encouraging Results from 99mTc -EC-G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease

CENTENNIAL, Colo., April 9, 2013—Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study…

Read